Acute withdrawal syndrome in a butorphanol treated patient. An adverse combination of opioids?

2008 ◽  
Vol 101 (eLetters Supplement) ◽  
Author(s):  
Ayuko Igarashi
2008 ◽  
Vol 101 (1) ◽  
pp. 127-128 ◽  
Author(s):  
A. Igarashi ◽  
S. Amagasa ◽  
N. Yokoo ◽  
M. Sato

2005 ◽  
Vol 102 (6) ◽  
pp. 1281-1282 ◽  
Author(s):  
Bernard Delvaux ◽  
Yves Ryckwaert ◽  
Michel Van Boven ◽  
Marc De Kock ◽  
Xavier Capdevila

2018 ◽  
Vol 11 ◽  
pp. 117954761875802 ◽  
Author(s):  
A Suárez-Lledó ◽  
A Padullés ◽  
T Lozano ◽  
S Cobo-Sacristán ◽  
M Colls ◽  
...  

Most drugs that act on the central nervous system (CNS) require dose titration to avoid withdrawal syndrome. Tizanidine withdrawal syndrome is caused by adrenergic discharge due to its α2-agonist mechanism and is characterized by hypertension, reflex tachycardia, hypertonicity, and anxiety. Although tizanidine withdrawal syndrome is mentioned as a potential side effect of cessation, it is not common and there have been few reports. We present the case of a 31-year-old woman with tizanidine withdrawal syndrome after discontinuing medication prescribed for a muscle contracture (tizanidine). She showed high adrenergic activity with nausea, vomiting, generalized tremor, dysthermia, hypertension, and tachycardia. Symptoms were reversed and successful reweaning was achieved by restarting tizanidine followed by slow downward titration. Withdrawal syndrome should be considered when drugs targeting the CNS are suddenly stopped. Weaning regimens should be closely monitored for acute withdrawal reactions.


2019 ◽  
Vol 51 (Supplement) ◽  
pp. 120
Author(s):  
Raj Masih ◽  
Michael Landis ◽  
Barbra Masih ◽  
Kabeer Masih ◽  
Justin Bates

Sign in / Sign up

Export Citation Format

Share Document